Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer
一项针对既往接受过治疗的晚期不可切除转移性结直肠癌患者的 II 期随机研究,评估了 magrolimab 联合贝伐单抗-FOLFIRI 方案的疗效。
期刊:
影响因子:
doi:10.1016/j.esmogo.2026.100324
Fakih, M; Gill, S; Sampat, K; Chan, D L; Fisher, G; Cruz-Correa, M; Lenz, H-J; Garcia-Alfonso, P; Forget, F; Lonardi, S; Krauss, J; Chen, E; Cubillo Gracian, A; Liu, Y; van Buuren, N; Shao, J; Dong, M; Chen, A; Tejani, M; Hecht, J R